CYPH (Cypherpunk Technologies Inc. Common Stock) Stock Analysis - News
Cypherpunk Technologies Inc. Common Stock (CYPH) is a publicly traded the market company. As of May 21, 2026, CYPH trades at $1.27 with a market cap of $110.72M and a P/E ratio of 17.64. CYPH moved +16.51% today. Year to date, CYPH is +11.40%; over the trailing twelve months it is flat. Its 52-week range spans $0.50 to $3.70. Rallies surfaces CYPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CYPH news today?
Cypherpunk Grows Zcash Treasury to 314,185.70 ZEC and Secures Sirexatamab Fast Track: Cypherpunk Technologies increased its Zcash treasury holdings to 314,185.70 ZEC after purchasing 10,279.30 ZEC for $5 million and invested $5 million in Zcash Open Development Labs. Leap Therapeutics’ sirexatamab secured FDA Fast Track designation following a Phase 2 study showing 42% ORR and HR 0.47 in DKK1-high colorectal cancer.
Mirabelli Christopher sold 60.00K (~$42.63K) on Mar 26, 2026.
Mirabelli Christopher sold 261.84K (~$822.18K) on Nov 17, 2025.
Mirabelli Christopher sold 414.48K (~$1.30M) on Nov 17, 2025.
CYPH Analyst Consensus
CYPH analyst coverage data. Average price target: $0.00.
Common questions about CYPH
What changed in CYPH news today?
Cypherpunk Grows Zcash Treasury to 314,185.70 ZEC and Secures Sirexatamab Fast Track: Cypherpunk Technologies increased its Zcash treasury holdings to 314,185.70 ZEC after purchasing 10,279.30 ZEC for $5 million and invested $5 million in Zcash Open Development Labs. Leap Therapeutics’ sirexatamab secured FDA Fast Track designation following a Phase 2 study showing 42% ORR and HR 0.47 in DKK1-high colorectal cancer.
Does Rallies summarize CYPH news?
Yes. Rallies summarizes CYPH news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CYPH research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CYPH. It does not provide personalized investment advice.
